Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A
Highlights: • Incannex have engaged Curia to scale up cGMP fill-finish manufacture of IHL-216A • Engagement of Curia follows achievement… Read more
Highlights: • Incannex have engaged Curia to scale up cGMP fill-finish manufacture of IHL-216A • Engagement of Curia follows achievement… Read more
Melbourne, Australia, July 27, 2022 – Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), (‘Incannex’ or… Read more
Highlights: • Bellberry human research ethics committee approved the phase 1 clinical trial investigating safety and pharmacokinetics of IHL-675A on… Read more
Highlights: • Bellberry human research ethics committee approved the phase 1 clinical trial investigating safety and pharmacokinetics of IHL-675A on… Read more
Highlights: • IHL-42X reduced primary endpoint apnoea hypopnea index relative to baseline at all three doses that were assessed •… Read more
Incannex (NASDAQ: IXHL) (ASX: IHL) announced positive results from the phase 2 clinical trial investigating the effect of IHL-42X for… Read more
Melbourne, Australia, May 17, 2022 – Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical… Read more
The acquisition of APIRx delivers a strong portfolio of patented drug candidates, with 22 development programs covering a total addressable… Read more
Melbourne, Australia, May 12, 2022 – Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical… Read more